Quantum BioPharma Ltd (NASDAQ:QNTM)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 0.70. At the close of trading, the stock’s price was $17.06, to imply a decrease of -10.96% or -$2.1 in intraday trading. The QNTM share’s 52-week high remains $38.25, putting it -124.21% down since that peak but still an impressive 84.17% since price per share fell to its 52-week low of $2.70. The company has a valuation of $46.23M, with an average of 0.45 million shares in intraday trading volume over the past 10 days and average of 244.08K shares over the past 3 months.

Quantum BioPharma Ltd (NASDAQ:QNTM) trade information

After registering a -10.96% downside in the last session, Quantum BioPharma Ltd (QNTM) has traded red over the past five days. The 5-day price performance for the stock is -19.22%, and 10.38% over 30 days. With these gigs, the year-to-date price performance is 91.59%. Short interest in Quantum BioPharma Ltd (NASDAQ:QNTM) saw shorts transact 0.14 million shares and set a 0.51 days time to cover.

QNTM Dividends

Quantum BioPharma Ltd has its next earnings report out on 2025-May-14. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Quantum BioPharma Ltd (NASDAQ:QNTM)’s Major holders

Quantum BioPharma Ltd insiders hold 11.41% of total outstanding shares, with institutional holders owning 23.49% of the shares at 26.52% float percentage. In total, 23.49% institutions holds shares in the company.

Going by data provided on Apr 30, 2025, AdvisorShares Trust-AdvisorShares Psychedelics ETF holds roughly 66.99 shares. This is just over 2.30% of the total shares, with a market valuation of $1.14 million